WallStreetZenWallStreetZen

NASDAQ: GLMD
Galmed Pharmaceuticals Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GLMD stock forecasts and price targets.

Forecast return on equity

Is GLMD forecast to generate an efficient return?

Company
N/A
Industry
350.65%
Market
211.89%

Forecast return on assets

Is GLMD forecast to generate an efficient return on assets?

Company
N/A
Industry
116.31%

GLMD earnings per share forecast

What is GLMD's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.87
Avg 2 year Forecast
-$0.56

GLMD revenue forecast

What is GLMD's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

GLMD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLMD$0.75N/AN/A
GNPX$1.75N/AN/A
SLRX$0.65N/AN/A
IMRN$0.76N/AN/A
MTNB$0.59N/AN/A
View Top Biotech Stocks

Galmed Pharmaceuticals Stock Forecast FAQ

What is GLMD's earnings growth forecast for 2026-2027?

(NASDAQ: GLMD) Galmed Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 67.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.64%.

Galmed Pharmaceuticals's earnings in 2025 is -$8,700,000.On average, 3 Wall Street analysts forecast GLMD's earnings for 2026 to be -$4,750,493, with the lowest GLMD earnings forecast at -$4,564,199, and the highest GLMD earnings forecast at -$4,890,214.

In 2027, GLMD is forecast to generate -$3,073,849 in earnings, with the lowest earnings forecast at -$2,953,306 and the highest earnings forecast at -$3,164,256.

If you're new to stock investing, here's how to buy Galmed Pharmaceuticals stock.

What is GLMD's revenue growth forecast for 2026-2028?

(NASDAQ: GLMD) Galmed Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.

Galmed Pharmaceuticals's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast GLMD's revenue for 2026 to be $0, with the lowest GLMD revenue forecast at $0, and the highest GLMD revenue forecast at $0. On average, 3 Wall Street analysts forecast GLMD's revenue for 2027 to be $0, with the lowest GLMD revenue forecast at $0, and the highest GLMD revenue forecast at $0.

In 2028, GLMD is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is GLMD's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GLMD) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 116.31%.

What is GLMD's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: GLMD) Galmed Pharmaceuticals's current Earnings Per Share (EPS) is -$3.55. On average, analysts forecast that GLMD's EPS will be -$0.87 for 2026, with the lowest EPS forecast at -$0.83, and the highest EPS forecast at -$0.89. In 2027, GLMD's EPS is forecast to hit -$0.56 (min: -$0.54, max: -$0.58).

What is GLMD's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GLMD) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.